Levodopa prolongs life expectancy and is non-toxic to substantia nigra

Parkinsonism and Related Disorders

Volumn 8, Issue 2, 2001, Pages 95-100

  Rajput, Ali H ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

AUTOPSY; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DYSTONIA; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CADAVER; CHILD; DISEASE PROGRESSION; DYSTONIA; FEMALE; HUMANS; LEVODOPA; LONGEVITY; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; RETROSPECTIVE STUDIES; SUBSTANTIA NIGRA; SURVIVAL ANALYSIS; TREMOR;

EID: 0034899258     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00023-2     Document Type: Conference Paper

References (30)

1. Is idiopathic parkinsonism the consequence of an event or a process
2. Parkinsonism: Onset, progression, and mortality
3. Disability and progression of Parkinson's disease
4. Ageing and Parkinson's disease: Substantia nigra regional selectivity
5. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain: Their behaviour in extrapyramidal system diseases
6. The effect of L-3,4-dihydroxyphenylalanine ( = L-DOPA) on akinesia in Parkinsonism
7. Aromatic amino acids and modification of parkinsonism
8. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases
9. Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease
10. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
11. The pathology of parkinsonism: A comparison of degenerations in cerebral cortex and brainstem
12. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
13. L-DOPA cytotoxicity to PC12 cells in culture is via its autoxidation
14. Glia conditioned medium protects fetal rat midbrainneuronesin culture from L-DOPA toxicity
15. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse
16. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically
17. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
18. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine
19. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice
20. Timely levodopa (LD) administration prolongs survival in Parkinson's disease
21. Dopa-responsive dystonia: Pathological and biochemical observations in a case
22. Chronic low dose therapy in Parkinson's disease: An argument for delaying levodopa therapy
23. Unified Parkinson's disease rating scale
24. Is levodopa toxic to human substantia nigra?
25. Dopa-responsive-non-progressive, juvenile parkinsonism: Report of a case
26. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence
27. Pulmonary embolism: An under-recognized yet frequent cause of death in parkinsonism
28. Significance of parkinsonian manifestations in essential tremor
29. Clinicopathological observations in essential tremor. Report of 6 cases
30. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia